Top

Published in:

01-01-2015 | Original Article

Esophageal COX-2 Expression Is Increased in Barrett’s Esophagus, Obesity, and Smoking

Authors: Theresa Nguyen, Zhouwen Tang, Mamoun Younes, Abeer Alsarraj, David Ramsey, Stephanie Fitzgerald, Jennifer R. Kramer, Hashem B. El-Serag

Published in: Digestive Diseases and Sciences | Issue 1/2015

Abstract

Background

Increased esophageal cyclooxygenase-2 (COX-2) expression has been associated with Barrett’s esophagus (BE); however, it is unknown whether COX-2 expression varies among patient groups with different clinical or socio-demographic factors.

Methods

We conducted a case–control study among eligible patients scheduled for elective esophagogastroduodenoscopy and patients eligible for screening colonoscopy recruited from primary clinics. We compared 39 BE tissue samples and 47 squamous tissue samples from BE cases and 240 squamous tissue samples from controls. Clinical and socio-demographic data were prospectively collected. Immunohistochemical staining for esophageal COX-2 was performed and scored.

Results

The median COX-2 score was significantly higher in BE tissue than squamous tissue from cases or controls (p < 0.001). Median COX-2 expression levels were higher in tissue samples from participants with a waist-to-hip ratio (WHR) in the 2nd tertile [unadjusted odds ratio (OR) 2.04; 95 % confidence interval (95 % CI) 1.17–3.57] and 3rd tertile (unadjusted OR 2.24; 95 % CI 1.20–4.16) compared with the 1st tertile and from current smokers compared with former or non-smokers (unadjusted OR 1.68; 95 % CI 1.03–2.75). In the multivariate analysis, WHRs in the 2nd tertile (OR 1.92; 95 % CI 1.07–3.45) and the 3rd tertile (OR 2.14; 95 % CI 1.10–4.16) were associated with high COX-2 compared with the 1st tertile, as was current smoking (OR 1.78; 95 % CI 1.06–2.97) compared with former and non-smoking.

Conclusion

We found a significant association between elevated esophageal mucosa COX-2 levels and the presence of BE tissue, as well as between elevated COX-2 levels and high WHR and current tobacco smoking. This information may assist in identifying patients likely to benefit from chemoprevention with COX-2 inhibitors.

Cianchi F, Cortesini C, Fantappie O, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res. 2004;10:2694–2704.PubMedCrossRef

Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183–1188.PubMed

Ristimaki A, Honkanen N, Jankala H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280.PubMed

Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501.PubMedCrossRef

Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–716.PubMedCrossRef

Shirvani VN, Ouatu-Lascar R, Kaur BS, et al. Cyclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487–496.PubMedCrossRef

Zhang F, Altorki NK, Wu YC, et al. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology. 2001;121:139-9.CrossRef

Fujimara T, Ohta T, Oyama K, et al. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol. 2006;12:1336–1345.

Morris CD, Armstrong GR, Bigley G, et al. Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol. 2001;96:990–996.PubMed

10.

Taddei A, Fabbroni V, Pini A, et al. Cyclooxygenase-2 and inflammation mediators have a crucial role in reflux-related esophageal histological changes and Barrett’s esophagus. Dig Dis Sci. 2014;59:949–957.

11.

Abnet CC, Freedman ND, Kamangar F, et al. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009;100:551–557.PubMedCentralPubMedCrossRef

12.

Liao LM, Vaughan TL, Corley DA, et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology. 2012;142:442–452.PubMedCentralPubMedCrossRef

13.

Kramer JR, Fischbach LA, Richardson P, et al. Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett’s esophagus in white men. Clin Gastroenterol Hepatol. 2013;11:373–381.

14.

Garcia JM, Splenser AE, Kramer J, et al. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study. Clin Gastroenterol Hepatol. 2014;12:229–238.

15.

Singh S, Sharma AN, Murad MH, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1399–1412.

16.

Morrow E, Bushyhead D, Wassenaar E, et al. The impact of laparoscopic anti-reflux surgery in patients with Barrett’s esophagus. Surg Endosc. 2014. (Epub ahead of print). doi:10.1007/s00464-014-3601-z.

17.

Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA. Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg. 2003;238:458–464.

18.

Vallbohmer D, DeMeester SR, Oh DS, et al. Antireflux surgery normalizes cyclooxygenase-2 expression in squamous epithelium of the distal esophagus. Am J Gastroenterol. 2006;101:1458–1466.PubMedCrossRef

19.

Xing LL, Wang Zn, Jiang L, et al. Cyclooxygenase-2 polymorphism and colorectal cancer: -765G>C variant modifies risk associated with smoking and body mass index. World J Gastroenterol. 2008;14:1785–1789.PubMedCentralPubMedCrossRef

20.

Delage B, Rullier A, Capdepont M, et al. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr J. 2007;6:20.PubMedCentralPubMedCrossRef

21.

Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett’s esophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006;147:4505–4516.PubMedCrossRef

22.

Aiyer HS, Li Y, Harper N, et al. Molecular changes in the esophageal epithelium after a subchronic exposure to cigarette smoke in the presence of bile-acid reflux. Inhal Toxicol. 2011;23:304–311.PubMedCrossRef

23.

Huang RY, Chen GG. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim Biophys Acta. 2011;1815:158–169.PubMed

24.

Zong Y, Zhang ST, Zhu ST. Nicotine enhances migration and invasion of human esophageal squamous carcinoma cells which is inhibited by nimesulide. World J Gastroenterol. 2009;15:2500–2505.PubMedCentralPubMedCrossRef

25.

Shin VY, Wu WK, Ye YN, et al. Nicotine promotes gastric tumor growth and neovascularization by activating extracellular signal-regulated kinase and cyclooxygenase-2. Carcinogenesis. 2004;25:2487–2495.PubMedCrossRef

26.

Shin VY, Wu WK, Chu KM, et al. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol Cancer Res. 2005;3:607–615.PubMedCrossRef

27.

Liu ES, Shin VY, Ye YN, et al. Cyclooxygenase-2 in cancer cells and macrophages induces colon cancer cell growth by cigarette smoke extract. Eur J Pharmacol. 2005;518:47–55.PubMedCrossRef

28.

Liang Y, Liu JL, Wu Y, et al. Cyclooxygenase-2 polymorphisms and susceptibility to esophageal cancer: a meta-analysis. Tohoku J Exp Med. 2011;223:137–144.PubMedCrossRef

29.

Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.PubMedCrossRef

30.

Triadafilopoulos G, Kaur B, Sood S, et al. The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett’s oesophagus. Aliment Pharmacol Ther. 2006;23:997–1005.PubMedCrossRef

31.

Heath EI, Canto MI, Piantadosi S, et al. Secondary chemoprevention of Barrett’s esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007;99:545–557.PubMedCentralPubMedCrossRef

32.

Anderson LA, Johnston BT, Watson RGP, et al. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66:4975–4982.PubMedCrossRef

33.

Thrift AP, Pandeya N, Smith KJ, Green AC, Webb PM, Whiteman DC. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett’s oesophagus. Aliment Pharmacol Ther. 2011;34:1235–1244.PubMedCrossRef

34.

Omer ZB, Ananthakrishnan AN, Nattinger KJ, et al. Aspirin protects against Barrett’s esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol. 2012;10:722–727.PubMedCentralPubMedCrossRef

35.

Khalaf N, Nguyen T, Ramsey D, El-Serag HB. Nonsteroidal anti-inflammatory drugs and the risk of Barrett’s esophagus. Clin Gastroenterol Hepatol. 2014. doi:10.1016/j.cgh.2014.04.027.

Title: Esophageal COX-2 Expression Is Increased in Barrett’s Esophagus, Obesity, and Smoking
Authors: Theresa Nguyen
Zhouwen Tang
Mamoun Younes
Abeer Alsarraj
David Ramsey
Stephanie Fitzgerald
Jennifer R. Kramer
Hashem B. El-Serag
Publication date: 01-01-2015
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 1/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-014-3333-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

Transenteral Bowel Preparation for Colonoscopy Is More Comfortable than the Traditional Method with No Inferiority in Efficacy

Bowel Preparation: Is Endoscopic Administration Worth the Extra Risk?

Leukopenia Predicts Remission in Patients with Inflammatory Bowel Disease and Behcet’s Disease on Thiopurine Maintenance

Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan®: Validation in Chronic Hepatitis B

Influence of Post-Transplant Immunosuppressive Therapy on Gastrointestinal Transit Using Biomagnetic Method: A Pilot Study

Impact of Microscopic Duodenitis on Symptomatic Response to Helicobacter pylori Eradication in Functional Dyspepsia

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials